11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Oct
Jeg er 30 år og vælger her til aften at arbejde en ekstra time.  Det er godt nok lørdag aften, og vi..
21 Oct
BaliShag bidrager med det som man er på forummet for. Det er sørgeligt at se folk taler om sne i apr..
23 Oct
Hvorfor handler disse indlæg altid om at man mener at skatten er for høj, hvorfor er der aldrig noge..
22 Oct
Medvirk aktivt til at stoppe shorting. Shorting skaber INGEN værdi for menigmand. Kun manipulerende ..
22 Oct
Jeg tror på, at genmabs darzalex bliver godkendt som backbone i enhver myelomatosebehandling - snart..
22 Oct
Det sad jeg faktisk og analyserede den anden dag, efter at have læst samme rapport som dig.   Jeg s..
22 Oct
Da der med jævne mellemrum henvises til de tyske regler for "godkendelse" af hvilken medicin, der er..
20 Oct
Fantastisk at se hvordan alle spyfluerne kommer ud som horder over en hundelort når shorterne angrib..
24 Oct
Peter Plys siger: "Hvis man tænker rigtig meget, kan man nogen gange finde bekymringer, som man slet..
22 Oct
Den indgang til kinesiske aktier, har jeg haft lige siden jeg forlod Hong Kong i 2008. Men jeg boede..

NB Glbl Fltg Rte Inc : Transaction in Own Shares

25/10/2016 07:00:25
25 October 2016 NB Global Floating Rate Income Fund Limited (the "Company") Transaction in Own Shares The Company announces that pursuant to ..

HSBC Bank Plc : Form 8.5 (EPT/RI) - London Stock Exchange Group Plc - Amendment

24/10/2016 15:29:18

Alliance Trust PLC : Net Asset Value(s)

24/10/2016 13:47:28
ALLIANCE TRUST PLC                                    At the close of business on Friday 21 October 2016: The Company's NAV per ordinary share..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Companies shifting more R&D spending away from physical products to software and services: 2016 Global Innovation 1000 Study
DBV Technologies: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrangement announced on 21 July 2016
The Scottish Salmon Company: Board of Directors
CrossAmerica Partners LP: Declares 10th Consecutive Quarterly Distribution Increase

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 October 2016 09:32:37
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20161024.1 - EUROWEB2 - 2016-10-25 10:32:37 - 2016-10-25 09:32:37 - 1000 - Website: OKAY